Weldon Takes Compensation Hit Due To OTC Recalls, But J&J Touts His Steering
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's manufacturing woes nicked CEO William Weldon’s 2010 compensation, but so far the firm's board of directors continues to stand behind him.
You may also be interested in...
McNeil OTC Recalls Slice $900M From J&J's 2010 Sales
Recalled OTC drugs took a $900 million bite out of Johnson & Johnson's fiscal 2010 sales, including $300 million in the fourth quarter, contributing to what the company and analysts labeled disappointing earnings.
J&J/McNeil Done With Post-Recall Personnel Changes - CEO Weldon
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.
Along With All NDAs Submitted To US FDA In FY2023, Costs For OTC Switch Proposals Increase
Agency publishes Prescription Drug User Fee Act rates for FY2023, the first of five covered in reauthorization of program Congress approved on 30 September as legislation added to a continuing resolution to fund federal agencies through 16 December.